Literature DB >> 2407368

Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study.

L T Vlasveld1, J H Beynen, W Boogerd, W W Ten Bokkel Huinink, S Rodenhuis.   

Abstract

Brain metastases developed in a 40-year-old woman with relapsed ovarian cancer 2 years after cisplatin-based combination chemotherapy. After a single dose of 800 mg/m2 carboplatin, complete remission of the brain metastases occurred. A pharmacokinetic study during the second course revealed low levels of carboplatin in the cerebrospinal fluid.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2407368     DOI： 10.1007/bf00686244

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  10 in total

Review 1.  Central nervous system metastases in epithelial ovarian carcinoma.

Authors:  J Dauplat; R K Nieberg; N F Hacker
Journal:  Cancer       Date:  1987-11-15       Impact factor: 6.860

2.  Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry.

Authors:  A F LeRoy; M L Wehling; H L Sponseller; W S Friauf; R E Solomon; R L Dedrick; C L Litterst; T E Gram; A M Guarino; D A Becker
Journal:  Biochem Med       Date:  1977-10

Review 3.  Optimizing drug delivery to brain tumors.

Authors:  N H Greig
Journal:  Cancer Treat Rev       Date:  1987-03       Impact factor: 12.111

Review 4.  Current status of chemotherapy for ovarian carcinoma.

Authors:  W W ten Bokkel Huinink
Journal:  Eur J Cancer Clin Oncol       Date:  1988-04

5.  Central nervous system metastases in epithelial ovarian carcinoma.

Authors:  D M Larson; L J Copeland; R P Moser; J M Malone; D M Gershenson; J T Wharton
Journal:  Obstet Gynecol       Date:  1986-12       Impact factor: 7.661

6.  High-dose carboplatin in refractory ovarian cancer patients.

Authors:  R F Ozols; Y Ostchega; G Curt; R C Young
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

7.  Comparative distribution and excretion of carboplatin and cisplatin in mice.

Authors:  Z H Siddik; M Jones; F E Boxall; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Treatment of advanced ovarian cancer with cisplatin, adriamycin, and cyclophosphamide: effect of treatment and incidence of intracranial metastases.

Authors:  G T Budd; K D Webster; R R Reimer; P Martimbeau; R B Livingston
Journal:  J Surg Oncol       Date:  1983-11       Impact factor: 3.454

9.  Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.

Authors:  E Boven; W J van der Vijgh; M M Nauta; H M Schlüper; H M Pinedo
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

10.  Preclinical studies identifying carboplatin as a viable cisplatin alternative.

Authors:  K R Harrap
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111
  10 in total
  7 in total

1.  Cerebrospinal fluid concentrations of carboplatin in a patient without blood-brain barrier disruption.

Authors:  V Brunner; P Houyau; E Chatelut; H Roché; P Canal
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

2.  Phase II trial of cisplatinum and etoposide in brain metastases of solid tumors.

Authors:  N Viñolas; F Graus; B Mellado; L Caralt; J Estapé
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

Review 3.  The role of chemotherapy in the treatment of patients with brain metastases from solid tumors.

Authors:  J C Buckner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

Review 4.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

5.  Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study.

Authors:  A Olivi; M Gilbert; K L Duncan; B Corden; D Lenartz; H Brem
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.

Authors:  Robert J Morgan; Timothy Synold; Adam Mamelak; Dean Lim; Zaid Al-Kadhimi; Przemyslaw Twardowski; Lucille Leong; Warren Chow; Kim Margolin; Stephen Shibata; George Somlo; Yun Yen; Paul Frankel; James H Doroshow
Journal:  Cancer Chemother Pharmacol       Date:  2010-01-28       Impact factor: 3.333

7.  Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.

Authors:  E A Lien; K Wester; P E Lønning; E Solheim; P M Ueland
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.